Ocrelizumab for Multiple Sclerosis

(OSSIA Trial)

This trial tests a new method of administering ocrelizumab, a treatment for multiple sclerosis (MS), by injecting it under the skin instead of into a vein. Researchers aim to evaluate the effectiveness, safety, and patient satisfaction of this method. The trial includes individuals with either relapsing or primary progressive MS who have previously used a similar type of medicine and are switching treatments for reasons other than a poor response. Those diagnosed with MS and transitioning from a similar treatment may find this trial suitable. As a Phase 4 trial, the research focuses on understanding how this already FDA-approved and effective treatment can benefit more patients.

The trial does not specify if you need to stop taking your current medications, but it does require that you switch from another specific multiple sclerosis therapy to ocrelizumab. It's best to discuss your current medications with the trial team.

Research has shown that ocrelizumab, a treatment for multiple sclerosis (MS), is generally safe. Studies have treated over 6,000 patients with ocrelizumab, providing extensive information about its effects. Adverse events occur at a rate of about 230 per 100 patient-years, indicating that while some people might experience side effects, they are usually manageable. Infections occur at a rate of 71 per 100 patient-years, and serious side effects are less common, occurring about 8 times per 100 patient-years. These findings suggest that most people tolerate ocrelizumab well. It also maintains a favorable benefit-risk balance, meaning the benefits typically outweigh the risks.¹²³⁴⁵

Ocrelizumab is unique because it targets CD20-positive B cells, a specific type of immune cell involved in the progression of multiple sclerosis (MS). While most MS treatments, like interferons and glatiramer acetate, work by modulating the immune system, Ocrelizumab directly depletes these B cells, potentially reducing the immune response that damages nerve cells. Researchers are excited about Ocrelizumab because it has shown promising results in slowing down the progression of MS with a different mechanism of action, and it is administered subcutaneously, which may offer more convenience compared to intravenous options.

Research has shown that ocrelizumab, the treatment under study in this trial, effectively treats multiple sclerosis (MS). Over 5.5 years, studies found that patients experienced significantly fewer relapses, with a risk reduction of up to 70%. Long-term data indicates that more than three-quarters of patients with relapsing MS (RMS) remained stable without major disability progression for ten years. In primary progressive MS (PPMS), ocrelizumab slowed the disease's worsening. Other studies have confirmed these benefits, consistently showing fewer relapses and slower disease progression.⁶⁷⁸⁹¹⁰